How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,504 results for

Pharmaceutical Representative

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Which Pharmaceutical Sales Representatives’ Features do Slovenian Family Physicians Value? (PubMed)

Which Pharmaceutical Sales Representatives’ Features do Slovenian Family Physicians Value? One of the key strategies for marketing new drugs to physicians is personal selling by pharmaceutical sales representatives (PSRs).The aim of this study was to determine which features of PSR's are most valued by Slovenian family physicians (FPs).We performed a cross-sectional observational postal survey in FPs. We sent the invitation for cooperation in the study to all Slovenian FPs working in family

Full Text available with Trip Pro

2013 Acta Informatica Medica

142. Electronic Pharmaceutical Record Used for Medication Reconciliation by a Pharmacist Associated to the Anesthesiologist Consultation

disorders. However, access to comprehensive and reliable data concerning the consumption of health products by the patient represents a major challenge. The "Dossier Pharmaceutique" (DP) is an electronic pharmaceutical record including medications (prescribed medications, over the counter medications, complementary and alternative medicines) delivered by community pharmacists over a four month period. Hospital pharmacists have access to the DP of hospitalized patients in order to improve the quality (...) Electronic Pharmaceutical Record Used for Medication Reconciliation by a Pharmacist Associated to the Anesthesiologist Consultation Electronic Pharmaceutical Record Used for Medication Reconciliation by a Pharmacist Associated to the Anesthesiologist Consultation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have

2013 Clinical Trials

143. PRPP Model for Evaluation the Effect of Non-pharmaceutical Therapies

PRPP Model for Evaluation the Effect of Non-pharmaceutical Therapies PRPP Model for Evaluation the Effect of Non-pharmaceutical Therapies - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. PRPP Model (...) for Evaluation the Effect of Non-pharmaceutical Therapies The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01869712 Recruitment Status : Unknown Verified October 2013 by Huijuan Cao, Beijing University of Chinese Medicine. Recruitment status was: Recruiting First Posted : June 5, 2013 Last Update Posted

2013 Clinical Trials

144. Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products. (PubMed)

Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products. A validated method to predict lung deposition for inhaled medication from in vitro data is lacking in spite of many attempts to correlate in vitro and in vivo outcomes. By using an in vivo-like in vitro setup and analyzing inhalers from the same batches, both in vitro and in vivo, we wanted to create a situation where information from the in vitro (...) deposition was measured in healthy adults by pharmacokinetic methods.We could show that the amount of drug escaping filtration in a realistic throat model under realistic delivery conditions predicts the typical total lung deposition in trained healthy adult subjects in the absence of significant exhaled mass. We could further show that by using combinations of throat models and flow profiles that represent realistic deviations from the typical case, variations in ex-cast deposition reflect between

2013 Journal of aerosol medicine and pulmonary drug delivery

145. Modeling the impact of simulated educational interventions on the use and abuse of pharmaceutical opioids in the United States: a report on initial efforts. (PubMed)

Modeling the impact of simulated educational interventions on the use and abuse of pharmaceutical opioids in the United States: a report on initial efforts. Three educational interventions were simulated in a system dynamics model of the medical use, trafficking, and nonmedical use of pharmaceutical opioids. The study relied on secondary data obtained in the literature for the period of 1995 to 2008 as well as expert panel recommendations regarding model parameters and structure. The behavior (...) of the resulting systems-level model was tested for fit against reference behavior data. After the base model was tested, logic to represent three educational interventions was added and the impact of each intervention on simulated overdose deaths was evaluated over a 7-year evaluation period, 2008 to 2015. Principal findings were that a prescriber education intervention not only reduced total overdose deaths in the model but also reduced the total number of persons who receive opioid analgesic therapy

Full Text available with Trip Pro

2013 Health Education & Behavior

146. Changing Interactions Between Physician Trainees and the Pharmaceutical Industry: A National Survey. (PubMed)

Changing Interactions Between Physician Trainees and the Pharmaceutical Industry: A National Survey. Increasingly, medical school policies limit pharmaceutical representatives' access to students and gifts from drugmakers, but little is known about how these policies affect student attitudes toward industry.To assess interactions between trainees and the pharmaceutical industry, and to determine whether learning environment characteristics influence students' practices and attitudes.We (...) (OR = 0.51, 95 % CI: 0.38-0.68, p < 0.001), but the strength of institutional conflict of interest policies was not associated with this variable.Despite recent policy changes, a substantial number of trainees continue to receive gifts from pharmaceutical representatives. We found no relation between these outcomes and a school's policies concerning interactions with industry.

Full Text available with Trip Pro

2013 Journal of General Internal Medicine

147. The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids. (PubMed)

The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids. To describe benzodiazepine and prescription opioid use by clients of drug treatment services and the sources of pharmaceuticals they use.Structured face-to-face interviews on unsanctioned use of benzodiazepines and prescription opioids were conducted between January and July 2008.Convenience sample of treatment entrants who reported regular (an average of ≥ 4 days per week) and unsanctioned use (...) for benzodiazepines (78%, 113/144). Forging of prescriptions was extremely uncommon. A mean duration of 6.3 years (SD, 6.6 years) for benzodiazepines and 4.4 years (SD, 5.7 years) for prescription opioids was reported between first use and problematic use--a substantial window for intervention.Medical practitioners are an important source of misused pharmaceuticals, but they are not the main source of prescription opioids. This has implications for prescription drug monitoring in Australia: current plans

Full Text available with Trip Pro

2013 Medical Journal of Australia

148. Mergers and innovation in the pharmaceutical industry. (PubMed)

and acquisitions to disguise their dwindling prospects or gain R&D synergies. On the other hand, the increased concentration brought on by recent mergers may have contributed to the declining rate of innovation. In this paper, we consider the second of these causal relationships: the likely impact of the recent merger wave among the largest pharmaceutical companies on the rate of innovation. In other words, have recent mergers, which may have been taken in response to lagging innovation, represented a self (...) Mergers and innovation in the pharmaceutical industry. Conflicting trends confound the pharmaceutical industry. The productivity of pharmaceutical innovation has declined in recent years. At the same time, the cohort of large companies who are the leading engines of pharmaceutical R&D has become increasingly concentrated. The concurrent presence of these trends is not sufficient to determine causation. In response to lagging innovation prospects, some companies have sought refuge in mergers

2013 Journal of Health Economics

149. Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies. (PubMed)

regulatory letters (i.e. warning letters and notice of violation) to pharmaceutical companies. A regulatory letter represents the FDA's first official notification to a pharmaceutical company that the FDA has discovered a product or activity in violation of the FDCA.This study analyzed trends in the pharmaceutical-related regulatory letters released by the FDA during the period 1997-2011 and assessed differences in the average number and type of regulatory letters released during the last four federal (...) Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies. The United States (US) Food and Drug Administration (FDA) is responsible for the protection of the public health by assuring the safety, effectiveness and security of human drugs and biological products through the enforcement of the Federal Food, Drug and Cosmetic Act (FDCA) and related regulations. These enforcement activities include

Full Text available with Trip Pro

2013 BMC Health Services Research

150. Physicians' perceptions of medical representative visits in Yemen: a qualitative study. (PubMed)

Physicians' perceptions of medical representative visits in Yemen: a qualitative study. The pharmaceutical industry invests heavily in promotion, and it uses a variety of promotional strategies to influence physicians' prescribing decisions. Within this context, medical representatives (MRs) are the key personnel employed in promoting their products. One significant consequence of the interactions between physicians and medical representatives is a conflict of interests which may contribute (...) to the over prescribing of medications and thus negative effects on patients' health and economics. There is limited detailed information published on the reasons why physicians interact with pharmaceutical representatives. This study aims to qualitatively explore physicians' attitudes about interactions with medical representatives and their reasons for accepting the medical representatives' visits.In-depth interviews were used to gain a better understanding of physicians' perceptions of medical

Full Text available with Trip Pro

2013 BMC Health Services Research

151. How Promiscuous Are Pharmaceutically Relevant Compounds? A Data-Driven Assessment (PubMed)

with high-confidence activity data are only annotated with a single biological target, whereas 36% are known to act against multiple targets within the same family (i.e., closely related targets). However, only ~2% of bioactive compounds are promiscuous across different target families. Thus, despite general data sparseness, these findings indicate that highly promiscuous bioactive compounds only rarely occur. Because pharmaceutically relevant active compounds represent the pool from which drug (...) How Promiscuous Are Pharmaceutically Relevant Compounds? A Data-Driven Assessment Given the increasing notion of target promiscuity of bioactive compounds and polypharmacological drug behavior, a detailed analysis of publicly available compound activity data from medicinal chemistry sources was carried out to determine and quantify the degree of promiscuity of active compounds across all known human target families. The results are surprising. Approximately 62% of currently available compounds

Full Text available with Trip Pro

2012 The AAPS journal

152. The reliability of hospital and pharmaceutical data to assess prevalent cases of chronic obstructive pulmonary disease. (PubMed)

the older cases with a principal diagnosis. COPD cases with a contemporary asthma diagnosis were 3.1%. We found that pharmaceutical data increases COPD prevalence estimates 2.2-2.5 times. Hospitalization does not necessarily indicate COPD severity, COPD as a principal diagnosis confirmed with medicine prescription more likely represented true cases. Misclassification affects asthma cases to greater extent than COPD cases. (...) The reliability of hospital and pharmaceutical data to assess prevalent cases of chronic obstructive pulmonary disease. Identifying chronic obstructive disease (COPD) cases is required to estimate COPD prevalence, to enroll COPD cohorts and to estimate air pollution health effects. Administrative health data are frequently used to identify COPD cases, though their validity has not been satisfactorily assessed. This paper aims to assess the contribution of pharmaceutical data in detecting COPD

2012 COPD

153. Creative compliance in pharmaceutical markets: the case of profit controls. (PubMed)

Creative compliance in pharmaceutical markets: the case of profit controls. This article discusses the issue of creative compliance in pharmaceutical markets. In particular, we explore the case of profit controls in the UK as an indirect way of regulating prices of in-patent originators. We study creative compliance in the presence of profit controls, rather than price controls or the Pharmaceutical Price Regulation Scheme in general. We use lessons from the accounting literature to explain (...) firm behavior and reveal potential weaknesses in profit control regulation and use data to show changes in trends following the introduction of this policy. We demonstrate that in the presence of profit controls there is an incentive for producers to increase costs (leading to inefficiencies) or to inflate reported costs. We find some evidence that the behavior of pharmaceutical firms in the UK may have changed as a result of the introduction of profit controls. Although the evidence is in line

2012 Expert review of pharmacoeconomics & outcomes research

154. Pharmaceutical countermeasures have opposite effects on the utricles and semicircular canals in man. (PubMed)

Pharmaceutical countermeasures have opposite effects on the utricles and semicircular canals in man. Sensory conflicts in the vestibular system lead to motion sickness of which space motion sickness (SMS) is a special case. SMS affects up to 70% of the astronauts during the first 3 days in space. The search for effective countermeasures has led to several nonpharmacological and pharmacological approaches. The current study focuses on the effects of lorazepam (1 mg), meclizine (25 mg (...) function was characterized by the vestibulo-ocular reflex (VOR) gain measured during earth vertical axis rotation as well as the total caloric response. The function of the utricles was represented by the utricular sensitivity, reflecting the ocular counter roll relative to the virtual induced head tilt.Promethazine significantly decreased the semicircular canal and utricular parameters. Both scopolamine and lorazepam caused only a decrease in the utricular sensitivity, whereas meclizine only decreased

2012 Audiology & neuro-otology

155. Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia. (PubMed)

Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia. Pharmaceutical representatives provide medicines information on their promoted products to doctors. However, studies have shown that the quality of this information is often low. No study has assessed the medicines information provided by pharmaceutical representatives to doctors in Malaysia and no recent evidence in Australia is present. We aimed to compare the provision (...) of medicines information by pharmaceutical representatives to doctors in Australia and Malaysia.Following a pharmaceutical representative's visit, general practitioners in Australia and Malaysia who had agreed to participate, were asked to fill out a questionnaire on the main product and claims discussed during the encounter. The questionnaire focused on provision of product information including indications, adverse effects, precautions, contraindications and the provision of information

Full Text available with Trip Pro

2010 BMC Public Health

156. An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals (PubMed)

An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals This review presents a comprehensive overview on selected synthetic routes towards commercial drug compounds as published in both journal and patent literature. Owing to the vast number of potential structures, we have concentrated only on those drugs containing five-membered heterocycles and focused principally on the assembly of the heterocyclic core. In order to target the most representative

Full Text available with Trip Pro

2011 Beilstein journal of organic chemistry

157. Syracuse Restaurant Becomes "Pharmaceutical Dinner Facility"

Syracuse Restaurant Becomes "Pharmaceutical Dinner Facility" The Carlat Psychiatry Blog: Syracuse Restaurant Becomes "Pharmaceutical Dinner Facility" | Keeping Psychiatry Honest Since 2007 Thursday, August 18, 2011 Syracuse Restaurant Becomes "Pharmaceutical Dinner Facility" In a rather embarrassing attempt to raise revenues, a restaurant in Syracuse, New York, is now explicitly marketing itself as a purveyor of drug company dinners. Francesca's Cucina, "Located in the heart of Syracuse's (...) they are encouraging drug reps to buy doctors: Yes, as they say on their website, "Francesca's Cucina is the premier facility for pharmaceutical dinners in the greater Syracuse area." It's a sad state of affairs when a restaurant brags about such a thing. Hat tip to Steve Balt, MD for alerting me to this website. at 8 comments: said... I would love to know how business is? Even the guys I know who used to frequent those dinners no longer go. I wonder if we got enough money together to hold an "antipharm dinner

2011 The Carlat Psychiatry Blog

158. Compliance to antifracture treatments in Tuscany: a regional survey based on institutional pharmaceutical dataset (PubMed)

Compliance to antifracture treatments in Tuscany: a regional survey based on institutional pharmaceutical dataset compliance to any antifracture therapy is the most important parameter affecting the effectiveness of the treatment. The aim of this study was to evaluate patients compliance to antifracture therapies in the whole Tuscany population who benefit from treatments reimbursed by the Regional Healthcare System.we have analyzed all antifracture drug prescriptions recorded in Tuscany (...) regional pharmaceutical database concerning year 2009, from both in-hospital distribution database (direct drug delivery, FED), and private pharmacies across the whole region (SPF). Patients who started the treatment in 2008 and those continuing it in 2010 were also considered in the analysis. The sample size consisted in 92,250 people (1:9 male to female ratio). Compliance to antifracture treatments at 3, 6, 9, and 12 months was analyzed by single drug (using the defined daily dose, DDD), and by age

Full Text available with Trip Pro

2011 Clinical Cases in Mineral and Bone Metabolism

159. Safety of a universal, virus-inactivated and prion-depleted, pharmaceutical-quality plasma: a randomized, double-blind, clinical trial in healthy volunteers. (PubMed)

Safety of a universal, virus-inactivated and prion-depleted, pharmaceutical-quality plasma: a randomized, double-blind, clinical trial in healthy volunteers. Universal plasma is intended to be transfused irrespective of the blood group. We compared the safety and tolerability of a novel, universal blood group-independent plasma with an ABO-matched plasma.In this randomized, double-blind, active-controlled, crossover, Phase I trial, 30 healthy adult volunteers (blood group A, B, or AB) were (...) subjects experienced dyspnea, leading to the withdrawal from the study of one subject.Universal plasma was equivalent to ABO-matched plasma with respect to safety and tolerability. Eliminating the risk of ABO incompatibility, this universal plasma represents an advance over blood group-specific plasma.© 2010 American Association of Blood Banks.

2011 Transfusion

160. The pharmaceutical corporation and the 'good work' of managing women's bodies. (PubMed)

aspect of the doctor's work, portraying pharmaceutical corporations as the physician's "natural partner", and women patients as passive, disempowered objects of medical practice. Through these consistent messages, the print magazine ORGYN represented one important set of mechanisms by which a pharmaceutical corporation helped drive and sustain medicalization. The article ends with a consideration of the implications of ORGYN's messages for companies, doctors, women patients, and the study (...) The pharmaceutical corporation and the 'good work' of managing women's bodies. Pharmaceutical companies are intricately intertwined with every aspect of contemporary medical reality, and they increasingly drive the social process of medicalization in order to establish and dominate markets for their drugs and devices. In addition to funding the majority of clinical research, organizing it to generate an evidence base that favors their innovations, and influencing the regulation

2011 Social Science & Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>